One-Year Outcome of Multiple Blood-Brain Barrier Disruptions with Temozolomide for the Treatment of Glioblastoma
Dr. Jin Woo Chang’s group reports one-year follow-up data on the six patients enrolled in their groundbreaking clinical trial to open the blood-brain barrier (BBB) prior to chemotherapy administration. Before enrollment, each patient had undergone gross total resection of the tumor. From September 2018 to January 2019, five patients underwent a total of six cycles of BBB disruption during standard adjuvant temozolomide (TMZ) therapy. One patient underwent three cycles of BBB disruption but continued with TMZ chemotherapy. The procedure proved to be safe with a survival rate of 100 percent up to one year. The tumor recurred in two of the patients at 11 and 16 months, respectively. What are the next steps?
See Frontiers in Oncology >